Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Rating of “Hold” by Analysts

Design Therapeutics, Inc. (NASDAQ:DSGN) has been assigned a consensus rating of “Hold” from the six research firms that are covering the firm, Marketbeat reports. Five research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $6.60.

A number of equities research analysts have weighed in on DSGN shares. Wedbush reiterated a “neutral” rating and set a $5.00 target price on shares of Design Therapeutics in a research note on Wednesday, March 20th. Royal Bank of Canada reissued a “sector perform” rating and issued a $4.00 target price on shares of Design Therapeutics in a report on Wednesday, March 20th. Finally, Piper Sandler upgraded Design Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $6.00 to $12.00 in a research note on Tuesday, May 7th.

Institutional Investors Weigh In On Design Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DSGN. RTW Investments LP increased its stake in shares of Design Therapeutics by 60.8% in the third quarter. RTW Investments LP now owns 2,512,986 shares of the company’s stock worth $5,931,000 after purchasing an additional 949,955 shares in the last quarter. Baker BROS. Advisors LP lifted its position in shares of Design Therapeutics by 10.8% in the first quarter. Baker BROS. Advisors LP now owns 1,662,120 shares of the company’s stock valued at $6,698,000 after acquiring an additional 162,120 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Design Therapeutics by 29.0% in the first quarter. Vanguard Group Inc. now owns 1,285,962 shares of the company’s stock worth $5,182,000 after acquiring an additional 288,803 shares during the period. BML Capital Management LLC purchased a new stake in shares of Design Therapeutics during the fourth quarter worth about $2,728,000. Finally, Acadian Asset Management LLC raised its stake in Design Therapeutics by 123.3% during the 1st quarter. Acadian Asset Management LLC now owns 403,546 shares of the company’s stock valued at $1,625,000 after purchasing an additional 222,805 shares during the period. Institutional investors own 56.64% of the company’s stock.

Design Therapeutics Price Performance

Shares of NASDAQ:DSGN opened at $3.20 on Friday. Design Therapeutics has a 1 year low of $1.94 and a 1 year high of $8.31. The company has a market cap of $180.77 million, a P/E ratio of -3.05 and a beta of 1.82. The stock’s fifty day moving average price is $3.92 and its 200-day moving average price is $3.25.

Design Therapeutics (NASDAQ:DSGN) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.08. On average, sell-side analysts anticipate that Design Therapeutics will post -1.02 earnings per share for the current year.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.